A specific probiotic strain, Bifidobacterium pseudocatenulatum CL256B, converts the poorly absorbed citrus flavanone hesperidin into its bioactive form hesperetin with ~90% efficiency via paired rhamnosidase and glucosidase enzymes. In naturally aging mice fed a Western diet for six months, hesperetin derived this way activated CISD2 — a pro-longevity gene that declines with age — alongside SIRT1 and HNF4α liver signaling, producing measurable improvements in grip strength, lean mass, adiposity, hepatic steatosis, glucose tolerance, and insulin sensitivity.
This work sits at a productive intersection of gut microbiome biology and flavonoid pharmacology. The CISD2 pathway is a relatively underexplored but mechanistically credible longevity target: its loss accelerates aging phenotypes in rodents, and activating it with small molecules has shown promise in earlier work from the same research group. The strength here is identifying a specific microbial mechanism — not just associating gut bacteria with health — and linking it to a defined molecular pathway.
That said, important caveats apply. All data are from animal models; human translation is unproven. The intervention delivers purified probiotic-derived hesperetin rather than testing oral hesperidin supplementation with the probiotic colonized in the gut, which is what humans would actually do. Individual gut microbiome composition will also affect conversion rates enormously. This is incremental but directionally compelling — it provides a testable human hypothesis that combining hesperidin-rich citrus intake with targeted Bifidobacterium supplementation could support metabolic healthspan.